The short version
7 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Doxorubicin Hydrochloride
Doxorubicin Hydrochloride · DOXORUBICIN HYDROCHLORIDE 2 mg/mL · Injection, Solution · Intravenous · Fresenius Kabi USA, LLC
NDC 63323-0883-10 · 1 VIAL, SINGLE-DOSE in 1 CARTON / 10 mL in 1 VIAL, SINGLE-DOSE · ANDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$26.00
Reported to Texas DSHS · 2026 annual filing · Fresenius Kabi USA
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- Fresenius Kabi USA, LLCUnited Statesmanufacture
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- ANDA063277
- TE code
- AP
- Approval date
- Oct 26, 1995
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
- Class III · TerminatedNov 17, 2020Fresenius Kabi USA, LLC — Cross Contamination with Other Products: trace amounts of octreotide found during testing
Manufacturers of Doxorubicin Hydrochloride (Injection, Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Gland Pharma Limited | DOXORUBICIN HYDROCHLORIDE 2 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Hikma Pharmaceuticals USA Inc. | DOXORUBICIN HYDROCHLORIDE 2 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Actavis Pharma, Inc. | DOXORUBICIN HYDROCHLORIDE 2 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Sagent Pharmaceuticals | DOXORUBICIN HYDROCHLORIDE 2 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Pfizer Laboratories Div Pfizer Inc | DOXORUBICIN HYDROCHLORIDE 2 mg/mL | Jul 15, 2026 | Aug 31, 2026 |
| Sun Pharmaceutical Industries, Inc. | DOXORUBICIN HYDROCHLORIDE 2 mg/mL | Jul 15, 2026 | Aug 31, 2026 |
| Fresenius Kabi USA, LLC | DOXORUBICIN HYDROCHLORIDE 2 mg/mL | Jul 15, 2026 | Aug 28, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Doxorubicin Hydrochloride — NDC 63323-0883-10," retrieved September 3, 2026, https://drugdashboards.com/drug/63323088310.
Free to cite with attribution — see how the data is put together.